Biologic medications, specifically tumor necrosis factor-alpha (TNF-alpha) blockers, are considered a promising new therapy for the treatment of psoriatic arthritis (PsA), especially in people who have moderate to severe cases of the disease. For the most part, candidates for therapy with biologic response modifiers, or biologics, have not responded to or cannot tolerate more conventional forms of treatment. The following biologic agents are currently approved by the Food and Drug Administration (FDA) for the treatment of psoriatic arthritis:
Etanercept (Enbrel®)
became the first biologic medication approved by the FDA for treating the signs and symptoms of psoriatic arthritis in 2002. Now, Enbrel is also indicated for inhibiting the progression of joint destruction and improving physical function in patients who have psoriatic arthritis. Enbrel is a man-made protein that acts like a sponge, soaking up TNF-alpha and blocking it from causing inflammation. It is given as an injection that can be administered at home.
According to clinical studies, after six months of treatment, Enbrel was proven effective at reducing the number of tender and swollen joints in patients with psoriatic arthritis. Nearly two out of five patients experienced a 50 percent improvement in arthritis severity scores. These scores are based on the severity of swelling in and around the joints, joint tenderness, pain, physical function and morning stiffness.
Copyright 2009 NBC Health
Click here to read the rest of the article at HealthVideo.com
